|
|
Milton "Jack" Foust, Jr., MD
Assistant Professor
Department of Psychiatry and Behavioral Sciences
Medical University of South Carolina
P.O. Box 250861
67 President Street
Charleston, SC 2942
(843) 792-5907
Date of Birth: 20 July 1958
Education:
Residency Training-Department of Psychiatry, US Naval Hospital, Bethesda, MD; 8 August 1985 through 8 August 1988
Internship-USNH San Diego, CA; 1 July 1984 through 30 June 1985; (rotations in: Psychiatry, Internal Medicine, Pediatrics, Obstetrics and Gynecology, Orthopedics, Neurology, Primary Care Clinic, Adolescent Medicine Clinic, Emergency Room)
Medical School-Vanderbilt University, Nashville, TN; MD 11 May 1984
Undergraduate-Vanderbilt University, Nashville, TN; BA 9 May 1980
Major: Molecular Biology Minor: Mathematics
Honors: Magna Cum Laude, Phi Beta Kappa
Medical Licensure and Certification:
Maryland State Board of Physician Quality Assurance, #D33022, issued 7 November 1985
South Carolina Board of Medical Examiners, #19848, issued 15 December 1997
Georgia Medical Board, #045788, issued 12/23/99
DHEC: #21-9848, issued 8/13/99
DEA: BF5256385; issued 03/21/97
Board Certification: (Psychiatry) Diplomate, American Board of Psychiatry and Neurology,
#32746, issued June 1990.
Examiner for Part II examinations (general psychiatry) held May 1-2, 1995, Washington, DC.
BLS (CPR) Certification: issued 07/17/96
ACLS Certification: issued 11/14/96
ATLS Certification: issued 03/02/95
Professional Activities:
Current and previous activities have included direct patient care (medication management, ECT and individual and group psychotherapy); consultation to physicians, nurses, social workers and managers/supervisors in civilian and military settings; supervision of psychiatric residents; curriculum planning and teaching of medical students and residents, participation in planning and conduct of clinical research. Also involved in the planning and implementation of Tri-Service (Army, Navy, Air Force) integration of psychiatric services and GME in National Capitol Area. Previous assignments/positions have included:
Attending Physician, Institute of Psychiatry, Medical University of South Carolina, 67 President St., P.O. Box 250861,Charleston SC 29425 (07/98 - present)
Previously Chief of Psychiatry and Director of Psychiatric Services, North Arundel Hospital, Glen Burnie, Maryland, 07/97 - 06/98. Member of Sheppard-Pratt Physicians, PA (07/97 - 06/98). Direct supervisor: Bob Roca, MD, Medical Director, General Hospital Programs, Sheppard-Pratt Physicians, PA, Tel: (410) 938-4323
Chief, Adult Inpatient Psychiatric Services at the Walter Reed Army Medical Center, 11/96 - 06/97 (Awarded Navy-Marine Corps Commendation Medal 06/30/97. Selected for Commander, United States Naval Reserve 06/97. Released from active duty, 07/01/97.)
Head, Outpatient Division, Department of Psychiatry, National Naval Medical Center,
Bethesda, Maryland, 08/93 -11/94
Head, Mental Health Department, U.S. Naval Hospital Roosevelt Roads, Puerto Rico,
08/89 - 10/92
Head, Alcohol Rehabilitation Service, USNH Roosevelt Roads, 11/89 - 10/90
Staff Psychiatrist, USNH Roosevelt Roads, 09/88 - 09/92
Collateral Duties:
Assistant Residency Training Director, Department of Psychiatry, National Naval Medical center, Bethesda, Maryland; September 1994 to July 1995
Member, Family Advocacy Case Review Subcommittee (Spouse Abuse), National Naval Medical Center, Bethesda, Maryland; July 1993 to December 1994
Member, Medical Ethics Committee, National Naval Medical Center, Bethesda, Maryland; April 1993 through December 1994
Member and Assistant Chairman, Family Advocacy Case Review Subcommittee, USNH Roosevelt Roads; August 1990 through October 1, 1992
Chairman, Bioethics Review Committee, USNH Roosevelt Roads; August 1989 through October 1, 1992
Society Membership:
American Psychiatric Association (WPS)
Academic Appointments:
Assistant Professor, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, P.O. Box 250861, 67 President Street, Charleston, SC 29425; 07/98 - present
Assistant Professor, Department of Psychiatry, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland; 10 August 1993 to present
Courses:
Schizophrenia - Monthly lecture given to third-year medical students during psychiatry clerkship at MUSC, 09/99 - present
Instructor and Course Coordinator - Review of Basic Psychiatry (PGY-II), USUHS/Tri-Service Integrated Residency Program, 08/95 - 02/96
Introduction to Clinical Psychopharmacology - monthly didactic presentations given between 08/95 and 06/97 to USUHS MS-III's assigned to the WRAMC Inpatient Psychiatry Service
Publications:
Barrett, J. E. et al. (1989) Behavioral and neurochemical effects of the 5HT1A receptor ligand spiroxatrine. Psychopharmacology 97:319-325
Gleeson, S. et al. (1989) Behavioral studies with anxiolytic drugs VI. Effects on punished responding of drugs interacting with serotonin receptor subtypes. Journal of Pharmacology and Experimental Therapeutics. 250:809-817
Dunivin D and Foust M J. A case study from the DOD Psychopharmacology Demonstration Project: Mania and neurosyphilis. Professional Psychology: Research and Practice - accepted for publication 3/99
Research Activity:
Co-Investigator: "A Double-Blind Placebo-Controlled Haloperidol-Referenced Study of the safety and Efficacy of Three Doses of Iloperidone Administered to Schizophrenic Patients for 42 Days." (Study #300) Titan Pharmaceutical, 7/1997-7/2000 ($107,821), S. Craig Risch, PI.
Co-Investigator: "A 52 Week Open Extension Study Evaluating the Safety and Outcome of 40-80 mg BID or Oral CP88-059-1 (Ziprasidone) daily in the Treatment of Subjects Who Have Participated in Previous CP-88,059-1 Clinical Trials." Study #128-116B-590, Pfizer 9/94 - 9/96 ($20,000).
Co-Investigator: "A Multicenter, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Lamotrigine Compared to Placebo and Lithium in the Treatment of an Acute Manic Episode in Patients Who Have Bipolar Disorder: Incorporating Participation in Genotype Research Which is Optional for Both Study Center and Patients." (Protocol # 609) Glaxo Wellcome, 10/97 - 9/99, ($133,556).
Co-Investigator: "A Phase III Double-Blind Placebo-Controlled Study of Aripiprazole in the Treatment of Psychosis." (Study 31-97-201) Otsuka America Pharmaceutical, Inc., 10/97 - 9/99 ($40,000).
Co-Investigator: "Double-Blind Evaluation of Risperidone vs Haloperidol in the Long-Term Morbidity of Early Psychotic Patients." (RIS-INT-35) Janssen Pharmaceutica, 7/97 - 7/2003, ($243,000).
Co-Investigator: "A Phase III, Randomized, Placebo-Controlled Study Evaluating the Safety and Outcome of Treatment With Oral Ziprasidone in Subjects with Mania." (Study # 601) Pfizer, 1/98 - 12/2001, ($156,712.50).
Co-Investigator: "An Open Extension Study Evaluating the Safety and Outcome of 40-60 mg Daily of Oral Ziprasidone in the Treatment of Subjects Who Have Participated in Protocol 601." (Study # 601E)Pfizer, Inc., 6/98 - 5/01, ($40,753.60).
Co-Investigator: "A Double-Blind Multi-Center Controlled Study Comparing the Safety and Efficacy of Ziprasidone and Olanzapine to Placebo in Patients with Schizophrenia or Schizoaffective Disorder Needing Inpatient Care." (Study # R0548) Pfizer, Inc., 6/98 - 5/00, ($98,235.00).
Co-Investigator: "A Double-Blind Six Month Continuation Protocol for Subjects Who Successfully Completed Protocol #R-0548." (Study # R0570) Pfizer, Inc., 6/98 - 5/00, ($18,000).
Co-Investigator: "A Prospective, Randomized, Double-Blind, Placebo and Active-Controlled, Multicenter Study to Evaluate the Efficacy and 'Safety of Three Fixed Doses of Iloperidone (4,8, and 12 mg/d) Given B.I.D. for 42 Days to Schizophrenic Patients with Acute Exacerbation, Followed by a Double-Blind, Active-Controlled, Flexible-Dose Long-Term, 20 - Week Phase with Iloperidone (4, 8, 12, or 16 mg/d) Given q.d. Novartis Pharmaceuticals Corp., 8/98 - 5/02, ($699,340.50).
Co-Investigator: "A 52-Week (1 year), Open Extension Study Evaluating the Safety and Efficacy of Continued Administration of 40-160 mg Daily of Oral Ziprasidone in the Treatment of Subjects Who Have Participated in Previous Ziprasidone Clinical Trials." (Study # R0585) Pfizer, Inc., 6/98 - 5/00, ($18,000).
Co-Investigator: "Phase II, Six Week, Double-Blind, Placebo and Olanzapine-Controlled Study Evaluating the Safety and Efficacy of Oral CP-361, 428 in Schizophrenia and Schizoaffective Disorder." Pfizer, Inc., 5/99 - 6/99, ($388,741.50).
Co-Investigator: "Open-Label Extension Study of the Safety and Tolerability of RWJ-17021 in Subjects with Bipolar I disorder who Completed Protocol TOPMAT-PDMD-002 (RWJ-17021) (PROTOCOL TOPMAT-PDMD-003; PHASE II)". RWJohnson Pharmaceutical Research Institute, 10/98 - 9/00, ($69,558.00).
Co-Investigator: "A MultiCenter, Randomized, Double-Blind, Placebo-Controlled Study of 3 fixed Doses of Aripiprazole in the treatment of Patients with Acute Schizophrenia" Bristol-Myers Squibb, 11/99 - 8/02, ($424,000.).
Co-Investigator: "A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release Carbamazepine in Lithium-Failure Patients with Bipolar Disorder." Protocol 105.301, Shire Laboratories, 12/99 - 11/02, ($237,199).
Co-Investigator: "A Six-Month, Open-Label, Multicenter Study of Extended Release Carbamazepine in Patients with Bipolar Disorder - An Extension of Protocol 105.301" Protocol 105.303, Shire Laboratories.
Presentations:
Suicide Prevention/Family Advocacy (Domestic Violence)/Sexual Assault-presented to the National Naval Dental Center orientation class, 10/13/94
Psychopathology of Stress-presented to the NNMC Department of Occupational Medicine, 10/18/94
Psychiatry and Religion-presented to the Department of Psychiatry, NNMC, 4/27/95
Clinical Assessment and Management of Anxiety-presented to the medical staff of Patuxent River Naval Hospital 6/15/95
Depression - presented as part of community outreach program, North Arundel Health System, 10/08/97
Alcohol Withdrawal - presented to the Medical Staff, North Arundel Hospital, Glen Burnie, MD, 04/23/98
Areas of Special Interest:
Psychopharmacology, Medical Informatics, Organizational Change
Computing/Informatics Experience:
Familiar with DOS, MS Windows, Unix environments; Turbo Pascal , Java, C.
Familiar with text-based and graphical interfaces to Internet and World-Wide-Web (Lynx, Netscape).
Foreign Language:
Spanish (basic communication and interviewing skills)
Last update: 6/16/00